INTERNATIONAL MYELOMA FOUNDATION

As filed

Subsection

03

NTEE code

Z99Z

Classification

1000

Street

4400 COLDWATER CANYON AVE STE 300

These codes are the IRS's own and are shown exactly as filed. What each one means is in the Business Master File documentation (opens in a new tab).

Mission and programs · 2023

• RESEARCH - THE INTERNATIONAL MYELOMA FOUNDATION (IMF) IS THE LEADER IN GLOBALLY COLLABORATIVE MYELOMA RESEARCH. IMF SUPPORTS LAB-BASED RESEARCH AND HAS AWARDED OVER 156 GRANTS TO TOP JUNIOR AND SENIOR RESEARCH SCIENTISTS SINCE 1995. IN ADDITION, IMF BRINGS TOGETHER THE WORLD'S LEADING EXPERTS IN THE MOST SUCCESSFUL AND UNIQUE WAY THROUGH THE INTERNATIONAL MYELOMA WORKING GROUP, WHICH IS PUBLISHING IN PRESTIGIOUS MEDICAL JOURNALS, CHARTING THE COURSE TO A CURE, MENTORING THE NEXT GENERATION OF INNOVATIVE INVESTIGATORS, AND IMPROVING LIVES THROUGH BETTER CARE. IT IS CONSIDERED THE MOST PRESTIGIOUS ORGANIZATION FOR MYELOMA RESEARCHERS GLOBALLY. THE BLACK SWAN RESEARCH INITIATIVE IS A MULTINATIONAL CONSORTIUM OF LEADING MYELOMA EXPERTS WHO ARE HARNESSING NEW TECHNOLOGIES AND THE LATEST MYELOMA TREATMENTS TO FIND A PATHWAY TO A CURE. THE BLACK SWAN RESEARCH STRATEGY CAPITALIZES ON THE AVAILABILITY OF POTENT NOVEL THERAPIES AND THE ADVENT OF ULTRA-SENSITIVE TESTS TO MEASURE EXACTLY WHEN AND HOW THOSE THERAPIES ARE WORKING IN PATIENTS. THE BLACK SWAN RESEARCH INITIATIVE IS DEDICATED TO DEVELOPING NEW CURATIVE THERAPIES FOR MYELOMA.

  Expenses $8,037,016 · Grants $196,667

• EDUCATION AND AWARENESS - ALTHOUGH IT IS THE SECOND MOST COMMON BLOOD CANCER, MULTIPLE MYELOMA IS STILL A RELATIVELY UNKNOWN DISEASE. FOR MANY PATIENTS AND THEIR CAREGIVERS, IT IS AT DIAGNOSIS WHEN THEY FIRST HEARD THE WORD "MYELOMA". IMF RECOGNIZES THE NEED FOR COMPREHENSIVE EDUCATION PROGRAMS FOR BOTH THE PATIENT AND THE PHYSICIAN TO ENSURE THAT PATIENTS ARE DIAGNOSED CORRECTLY AND TREATED EFFECTIVELY. OUR LIBRARY OF MORE THAN 100 PUBLICATIONS FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS, IS AVAILABLE FREE OF CHARGE. PUBLICATIONS ARE UPDATED ANNUALLY AND AVAILABLE IN MORE THAN 19 INTERNATIONAL LANGUAGES. THE IMF EMPOWERS PATIENTS AND THEIR CAREGIVERS TO JOIN HEALTHCARE PROVIDERS AS ACTIVE DECISION-MAKING PARTNERS, LEADING TO THE BEST POSSIBLE QUALITY OF LIFE FOR EACH INDIVIDUAL MYELOMA PATIENT. THE IMF PRODUCES COMPREHENSIVE BUT 'USER-FRIENDLY' INFORMATION FOR THE ENTIRE MYELOMA COMMUNITY. THE IMF'S PUBLICATIONS LIBRARY INCLUDES AN EXTENSIVE CATALOG OF BOOKLETS, TIP CARDS, ARTICLES, WEBINARS AND TELECONFERENCES, BLOGS, DIGITAL MEDIA AND INTERVIEWS, ALL WRITTEN, CREATED, AND PRODUCED BY THE IMF WITH OVERSIGHT BY ITS SCIENTIFIC ADVISORY COMMITTEE. THE IMF LIBRARY'S BROAD SCOPE INCLUDES INFORMATION ABOUT MYELOMA TREATMENT OPTIONS, CLINICAL TRIALS, DIVERSITY, EQUITY AND QUALITY OF LIFE CONSIDERATIONS FOR PATIENTS AND PHYSICIANS.

  Expenses $2,745,423

• PATIENT AND FAMILY SEMINARS: THE IMF'S PATIENT AND FAMILY SEMINARS PRESENT VITAL INFORMATION ABOUT NEW TREATMENTS AND CLINICAL TRIALS, PROVIDE TIME WITH MYELOMA SPECIALISTS IN INTIMATE SETTINGS, AND ALLOW PARTICIPANTS TO SHARE THEIR PERSONAL EXPERIENCES AND SUPPORT. PREMIER MYELOMA EXPERTS VOLUNTEER THEIR TIME TO THE SEMINARS, TO EMPOWER PATIENTS AND THEIR FAMILIES TO MAKE EDUCATED TREATMENT CHOICES TAILORED TO THEIR NEEDS. IN ADDITION TO PATIENT AND FAMILY SEMINARS, THE IMF FACILITATES REGIONAL COMMUNITY WORKSHOPS, WHICH SERVE AS CONDENSED SEMINARS IN SMALLER CITIES TO EXPAND THE REACH OF IMF PROGRAMS AND UP-TO-DATE INFORMATION ON MYELOMA CARE, SUPPORT AND TREATMENT TO A WIDER AUDIENCE AT NO CHARGE.

  Expenses $1,819,716

• INTERNATIONAL - THE IMF GROWS ITS NETWORK OF HEALTH CARE PROFESSIONALS AROUND THE WORLD. KEY TEAM MEMBERS ORGANIZE PHYSICIAN AS WELL AS PATIENT MEETINGS IN ORDER TO PROVIDE EDUCATION ABOUT THE LATEST DEVELOPMENTS IN THE FIELD OF MULTIPLE MYELOMA.SUPPORT GROUPS - THROUGH A GLOBAL COMMUNITY OF VOLUNTARY SUPPORT GROUPS, THE IMF SEEKS TO ENSURE THAT PATIENTS AND FAMILIES HAVE LOCAL ACCESS TO SUPPORT AND EDUCATION. THE IMF CURRENTLY SUPPORTS OVER 300 SUPPORT GROUPS WORLDWIDE. THE IMF OFFERS UNEQUALED WEBSITE CREATION AND HOSTING FOR LOCAL SUPPORT GROUPS, AND PROVIDED A UNIQUE OPPORTUNITY FOR SOME SUPPORT GROUP LEADERS TO ATTEND THE AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING. THE 25TH ANNUAL SUPPORT GROUP LEADERS SUMMIT TOOK PLACE WITH MORE THAN 90 LEADERS IN ATTENDANCE. TECHNOLOGY CONTINUES TO BE EMPHASIZED FOR SUPPORT GROUP LEADERS. THE IMF ALSO CONTINUED TO UPDATE ITS APP SPECIFICALLY DESIGNED FOR SUPPORT GROUP LEADERS WHICH OFFER MEETING AND EDUCATION MATERIALS ACCESSIBLE TO HELP BUILD EFFECTIVE COMMUNICANURSE - THE IMF NURSE LEADERSHIP BOARD IS A PROFESSIONAL PARTNERSHIP REPRESENTING NURSE EXPERTS CARING FOR MYELOMA PATIENTS AT LEADING MEDICAL CENTERS. FOUNDED IN NOVEMBER 2006, THE NLB HAS PROVEN TO BE INVALUABLE TO THE MYELOMA COMMUNITY AS A PLATFORM THAT BOLSTERS NURSING EDUCATION, CLINICAL CARE EXPERIENCE EXCHANGE, AND PATIENT KNOWLEDGE AND EMPOWERMENT IN AN EFFORT TO OPTIMIZE OUTCOMES FOR PATIENTS WITH MYELOMA. THIS BOARD OF EXPERIENCED MYELOMA NURSES HAS MADE GREAT STRIDES IN IMPROVING THE NURSING CARE AND SELF-CARE OF MYELOMA PATIENTS SINCE ITS INCEPTION.CLINICAL MEETINGS - IMF TEAM MEMBERS ORGANIZE CLINICAL MEETINGS, BRINGING TOGETHER THE WORLD'S LEADING MYELOMA EXPERTS, TO FORM A COALITION THAT WILL WORK COLLABORATIVELY ON MYELOMA-RELATED PROJECTS AND AVOID DUPLICATION OF EFFORTS AND DILUTION OF VALUABLE RESOURCES. THESE COALITIONS PROMOTE EXCELLENCE IN CLINICAL PRACTICE, RESEARCH AND EDUCATION AND CME-ACCREDITED MEDICAL EDUCATION PROGRAMS. THIS PAST YEAR ALSO INCLUDED EDUCATION TO THE COMMUNITY PHYSICIAN VIA ONLINE AND LIVE INSTRUCTION.ADVOCACY - THE IMF IS DEDICATED TO CREATING A GLOBAL COMMUNITY THAT SUPPORTS THE WIDE-RANGING NEEDS OF ALL AFFECTED BY MYELOMA. THE IMF ADVOCATES ON BEHALF OF THOSE AFFECTED BY MULTIPLE MYELOMA FOR AN INCREASE IN ACCESSIBILITY OF HIGH-QUALITY DIAGNOSTICS AND TREATMENTS, FOR FUNDING OF MYELOMA-RELATED RESEARCH, AND FOR AN END TO INSURANCE COVERAGE DISPARITIES FOR TREATMENT. THE IMF INCLUDES THE ENTIRE MYELOMA COMMUNITY IN THESE EFFORTS AND CONTINUES TO EXPAND ITS COMMITMENT TO EMPOWERING PATIENTS, FAMILIES, AND FRIENDS TO ADVOCATE ON BEHALF OF PATIENT RIGHTS.INFOLINE - THE IMF'S TOLL-FREE INFORMATION TELEPHONE LINE PROVIDES LIFE-SAVING AND LIFE-CHANGING MYELOMA TREATMENT AND MANAGEMENT SUPPORT FROM COMPASSIONATE, HIGHLY TRAINED SPECIALISTS. AS NEW TREATMENT OPTIONS ARE GAINING ATTENTION AND USE IN MULTIPLE MYELOMA, ANSWERING QUESTIONS ABOUT MYELOMA, ITS TREATMENT, DRUG SIDE EFFECTS, OPTIONS FOR POSSIBLE CLINICAL TRIALS OTHER HEALTH CONCERNS, AND WHERE TO FIND LOCAL SUPPORT IS MORE IMPORTANT THAN EVER.WEBSITE - THE IMF WEBSITE IS THE LEADING RESOURCE FOR MYELOMA-RELATED CONTENT AND THE MOST COMPLETE SOURCE OF ANSWERS FROM THE MANY QUESTIONS ASKED BY THOSE NEWLY DIAGNOSED TO THOSE MANAGING MYELOMA FOR MANY YEARS. THE WEBSITE CONSIDERS PATIENTS, CAREGIVERS, FAMILY MEMBERS, AND HEALTHCARE PROFESSIONALS. INFORMATION IS AVAILABLE IN MULTIPLE LANGUAGES AND FOCUS IS ON THE IMF'S RESEARCH, EDUCATION, SUPPORT AND ADVOCACY INITIATIVES. IMF LAUNCHED MYELO, THE IMF WEBSITE'S CHATBOX OR CHAT FEATURE DESIGNED TO PROVIDE GENERAL INFORMATION AND SUPPORT RELATED TO MULTIPLE MYELOMA. IT IS NOT INTENDED TO REPLACE PROFESSIONAL MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT FROM QUALIFIED HEALTHCARE PROVIDERS. SEE IMF WEBSITE FOR FURTHER INFORMATION. MYELOMA TODAY - MYELOMA TODAY IS A QUARTERLY NEWSLETTER AND THE GO-TO RESOURCE FOR THE MYELOMA COMMUNITY TO LEARN ABOUT THE LATEST ADVANCES IN MYELOMA TREATMENT, RESEARCH AND QUALITY OF LIFE ISSUES. IT IS PROVIDED FREE OF CHARGE.INFORMATIONAL MAILINGS - THE INFOPACK IS MADE UP OF A SELECTION OF THE IMF'S PUBLICATIONS AND IS DESIGNED TO PROVIDE NEWLY DIAGNOSED PATIENTS AND THEIR FAMILIES WITH A COMPLETE UNDERSTANDING OF THE DISEASE AND CARE. THE INFO PACK CONTAINS INFORMATIVE MATERIALS FREE OF CHARGE IN 19 LANGUAGES.

  Expenses $5,816,898 · Grants $32,000 · Revenue $18,667

As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here.

Officers and directors · 2023

As listed in Part VII of the 2023 return, in the order the filer printed them. Each return names its own; this is not a roster the organization keeps with us.

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us. Earlier years are each on their own filing page.

Filings

• 2023

  Revenue

  $18,983,815

  Expenses

  $20,796,076

  Contributions

  $18,582,456

  Grants paid

  $228,667

• 2022

  Revenue

  $16,745,686

  Expenses

  $18,411,117

  Contributions

  $16,285,176

  Grants paid

  $263,667

The four totals the IRS asks for on Part I of the Form 990, as filed. A dash means the figure was not present on the return — not that it was zero.

Other returns filed

• 2021 · 990

  Revenue

  $18,062,675

  Expenses

  $16,819,032

  Assets (EOY)

  $18,463,467

• 2020 · 990

  Revenue

  $17,434,390

  Expenses

  $14,439,887

  Assets (EOY)

  $20,383,236

• 2019 · 990

  Revenue

  $14,864,659

  Expenses

  $14,507,444

  Assets (EOY)

  $17,557,878

• 2019 · 990

  Revenue

  $14,864,659

  Expenses

  $14,722,445

  Assets (EOY)

  $17,342,878

• 2018 · 990

  Revenue

  $20,025,618

  Expenses

  $19,330,926

  Assets (EOY)

  $18,014,619

• 2017 · 990

  Revenue

  $16,804,022

  Expenses

  $16,883,907

  Assets (EOY)

  $16,649,778

• 2016 · 990

  Revenue

  $15,689,157

  Expenses

  $16,025,421

  Assets (EOY)

  $19,253,565

• 2015 · 990

  Revenue

  $22,367,091

  Expenses

  $15,822,035

  Assets (EOY)

  $21,865,280

• 2014 · 990

  Revenue

  $12,844,967

  Expenses

  $12,642,511

  Assets (EOY)

  $15,667,803

• 2013 · 990

  Revenue

  $11,031,927

  Expenses

  $10,512,021

  Assets (EOY)

  $14,174,327

Nonprofiteer parses Forms 990, 990-EZ and 990-PF, in a window of recent tax years. These returns are recorded from the IRS e-file index, so their figures were extracted by that index rather than read from the return here — treat them as a different source from the filings above, not as more of the same record. A dash means the index carries no figure; Form 990-T listings carry none at all. Showing the 10 most recent; the API carries the rest.

Grants made

• CASE WESTERN RESERVE UNIVERSITY

  $53,333

  2022 · NOVEL ADJUVANTS TO PROTEASOME INHIBITORS FOR MYELOMA THERAPY

• NEW YORK WEILL CORNELL MEDICAL CENTER FUND INC

  $53,333

  2023 · CHARACTERIZING THE ROLE AND TARGETING OF THE HISTONE METHYLTRANSFERASE SETD2 IN MULTIPLE MYELOMA.

• DANA FARBER CANCER INSTITUTE

  $33,333

  2022 · DEFINING CELL STATES UNDERLYING TREATMENT RESISTANCE IN MYELOMA BY INTEGRATING MULTIOMIC SEQUENCING DATA

• TRUSTEES OF BOSTON UNIVERSITY

  $33,333

  2023 · DEFINING A MOLECULAR SIGNATURE OF CARDIOTOXICITY IN SYSTEMIC IMMUNOGLOBIN LIGHT CHAIN AMYLOIDOSIS.

• THE GENERAL HOSPITAL CORPORATION

  $33,333

  2023 · ADVANCING SPINAL STABILITY IN MULTIPLE MYELOMA: A PREDICTIVE BIOMECHANICAL SIMULATION APPROACH.

• CASE WESTERN RESERVE UNIVERSITY

  $26,667

  2023 · DECIPHERING THE EPIGENOMIC MECHANISMS OF TRANSFORMATION FROM BENIGN MONOCLONAL GAMMAPATHIES TO SYMPTOMATIC MULTIPLE MYELOMA.

• UNIVERSITY OF SAN DIEGO

  $16,667

  2022 · TUNING THE INNATE IMMUNE MULTIPLE MYELOMA MICROENVIRONMENT BY MODULATING IRF4

• TRUSTEES OF BOSTON UNIVERSITY

  $16,667

  2022 · DEFINING A MOLECULAR SIGNATURE OF CARDIOTOXICITY IN SYSTEMIC IMMUNOGLOBIN LIGHT CHAIN AMYLOIDOSIS

• DANA FARBER CANCER INSTITUTE

  $16,667

  2023 · TUNING THE INNATE IMMUNE MULTIPLE MYELOMA MICROENVIRONMENT BY MODULATING IRF4

Where these grants went next →

Grants received

• AMERICAN ENDOWMENT FOUNDATION

  $99,000

  2024 · MEDICAL RESEARCH

• FIDELITY INVESTMENTS CHARITABLE GIFT FUND

  $93,775

  2024 · For grant recipient's exempt purposes

• DONOR ADVISED CHARITABLE GIVING

  $92,750

  2024 · HEALTH

• FIDELITY INVESTMENTS CHARITABLE GIFT FUND

  $92,035

  2022 · For grant recipient's exempt purposes

• FIDELITY INVESTMENTS CHARITABLE GIFT FUND

  $79,177

  2023 · For grant recipient's exempt purposes

• PINEBELT FOUNDATION

  $75,000

  2025 · SUPPORT

• AMERICAN ENDOWMENT FOUNDATION

  $54,000

  2023 · MEDICAL RESEARCH

• PINEBELT FOUNDATION

  $51,160

  2022 · SUPPORT

• PINEBELT FOUNDATION

  $50,000

  2024 · SUPPORT

• PINEBELT FOUNDATION

  $50,000

  2023 · SUPPORT

The 10 largest by cash amount. The API serves every itemized grant.

Other IRS files